Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia
- PMID: 20185182
- DOI: 10.1016/j.psychres.2009.05.004
Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia
Abstract
To assess baseline predictors and consequences of antipsychotic adherence during the long-term treatment of schizophrenia outpatients, data were taken from the 3-year, prospective, observational, European Schizophrenia Outpatients Health Outcomes (SOHO) study, in which outpatients starting or changing antipsychotics were assessed every 6 months. Physician-rated adherence was dichotomized as adherence/non-adherence. Regression models tested for predictors of adherence during follow-up, and associations between adherence and outcome measures. Of the 6731 patients analysed, 71.2% were adherent and 28.8% were non-adherent over 3 years. The strongest predictor of adherence was adherence in the month before baseline assessment. Other baseline predictors of adherence included initial treatment for schizophrenia and greater social activities. Baseline predictors of non-adherence were alcohol dependence and substance abuse in the previous month, hospitalization in the previous 6 months, independent housing and the presence of hostility. Non-adherence was significantly associated with an increased risk of relapse, hospitalization and suicide attempts. In conclusion, non-adherence is common but can partly be predicted. This may allow strategies to improve adherence to be targeted to high-risk patients. Also, reversal of some risk factors may improve adherence. Non-adherence is associated with a range of poorer long-term outcomes, with clinical and economic implications.
Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study.Psychiatry Res. 2011 Nov 30;190(1):110-4. doi: 10.1016/j.psychres.2011.04.016. Epub 2011 May 14. Psychiatry Res. 2011. PMID: 21571375
-
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.Eur Neuropsychopharmacol. 2007 Mar;17(4):235-44. doi: 10.1016/j.euroneuro.2006.09.005. Epub 2006 Nov 29. Eur Neuropsychopharmacol. 2007. PMID: 17137759 Clinical Trial.
-
Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up.Pharmacopsychiatry. 2007 Nov;40(6):264-8. doi: 10.1055/s-2007-992141. Pharmacopsychiatry. 2007. PMID: 18030650
-
Overview of the findings from the European SOHO study.Expert Rev Neurother. 2008 Jun;8(6):873-80. doi: 10.1586/14737175.8.6.873. Expert Rev Neurother. 2008. PMID: 18505352 Review.
-
[Therapeutic alliance, a stake in schizophrenia].Encephale. 2009 Feb;35(1):80-9. doi: 10.1016/j.encep.2007.12.009. Epub 2008 May 19. Encephale. 2009. PMID: 19250998 Review. French.
Cited by
-
The Impact of Paliperidone Palmitate on Hospitalization in Patients with Schizophrenia: A Retrospective Mirror-image Study.Clin Psychopharmacol Neurosci. 2019 Nov 20;17(4):531-536. doi: 10.9758/cpn.2019.17.4.531. Clin Psychopharmacol Neurosci. 2019. PMID: 31671491 Free PMC article.
-
Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic.Neuropsychiatr Dis Treat. 2023 Mar 17;19:623-634. doi: 10.2147/NDT.S394220. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 36959874 Free PMC article.
-
Effectiveness of More Personalized, Case-Managed, and Multicomponent Treatment for Patients with Severe Schizophrenia Compared to the Standard Treatment: A Ten-Year Follow-Up.J Pers Med. 2022 Jul 4;12(7):1101. doi: 10.3390/jpm12071101. J Pers Med. 2022. PMID: 35887598 Free PMC article.
-
Medication adherence in schizophrenia.World J Psychiatry. 2012 Oct 22;2(5):74-82. doi: 10.5498/wjp.v2.i5.74. World J Psychiatry. 2012. PMID: 24175171 Free PMC article. Review.
-
Studies on Haloperidol and Adjunctive α-Mangostin or Raw Garcinia mangostana Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male Rats.Front Psychiatry. 2020 Mar 31;11:121. doi: 10.3389/fpsyt.2020.00121. eCollection 2020. Front Psychiatry. 2020. PMID: 32296347 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical